Terbinafine

References

• Roberts DT. Prevalence of dematophyte onychomycosis in the United Kingdom: results of an omnibus survey. Br J Dermatology 1992;126(Suppl): 23–7
   Google Scholar
• Jones TC, Villars VV. Terbinafine. In Ryley JF, ed. Handbook of Experimental Pharmacology. Chemotherapy of Fungal Diseases, volume 96. Springer-Verlag, 1990:483–503
   Google Scholar
• Stütz A. Allylamine derivatives - a new class of active substances in antifungal chemotherapy. Angew Chem Int Ed Eng 1987;26:320–8
   Web of Science ®Google Scholar
• Brautigam M, Weidinger G. Clinical experience with naftifine. In Rippon JW, Frontling R, eds. Cutaneous Anti-fungal Agents. Clinical Dermatology. New York: Marcel Dekker, 1993:99–115
   Google Scholar
• Ryder NS. The mechanism of action of terbinafine. Clin Experimental Dermatology 1989;14:98–100
   PubMed Web of Science ®Google Scholar
• Petrany G, Ryder NS, Stutz A. Allylamine derivatives: new class of synthetic antifungal agents inhibiting fungal squalene epoxidase. Science 1984;224:1239–41
   PubMedGoogle Scholar
• Ciftci E, Guriz H, Aysev AD. Mupiricin vs terbinafine in impetigo. Indian J Pediatr 2002;69:679–82
   PubMedGoogle Scholar
• Lee WS, Chen RJ, Wang YJ, et al. In vitro and in vivo studies of the anticancer action of terbinafine in human cancer cell lines; GO/G1 p53-associated cell cycle arrest. Int J Cancer 2003;106:125–37
   PubMed Web of Science ®Google Scholar
• Hill S, Thomas R, Smith SG, et al. An investigation of the pharmacokinetics of topical terbinafine (Lamisil) 1% cream. Br J Dermatology 1992;127:396–400
   PubMed Web of Science ®Google Scholar
• Jensen JC. Clinical pharmacokinetics of terbinafine (Lamisil). Clin Experimental Dermatology 1989;14:110–3
   PubMed Web of Science ®Google Scholar
• Faergemann J, Zehender H, Jones T, et al. Terbinafine levels in serum, stratum corneum, dermis-epidermis (without stratum corneum), hair, sebum and eccrine sweat. Acta Derm Venereol 1990;71:322–6
   Google Scholar
• Finlay AY, Lever L, Thomas R, et al. Nail matrix kinetics of oral terbinafine in onychomycosis and normal nails. J Dermatol Treatment 1990;1(Suppl):51–3
   Google Scholar
• Ryder NS, Dupont M-C. Inhibition of squalene epoxidase by allylamine antimycotic compounds: a comparitive study of the fungal and mammalian enzymes. Biochemical J 1985;230:765–70
   PubMed Web of Science ®Google Scholar
• Schuster I, Ryder NS. Allylamines - mode and selectivity of action compared to azole antifungals and biological fate in mammalian organisms. J Dermatol Treat 1990;1(Suppl):7–9
   Google Scholar
• Van Der Kuy PH, Van Den Heuvel HA, Kempen RW, et al. Pharmacokinetic interaction between nortriptyline and terbinafine. Annals Pharmacotherapy 2002;36:1712–4
   Google Scholar
• Madani S, Barilla D, Cramer J, et al. Effect of terbinafine on the pharmacokinetics and pharmacodynamics of desipramine in healthy volunteers identified as cyto-chrome P4502D6 (CYP2D6) extensive metabolisers. J Clin Pharmacol 2002;42:1211–8
   PubMed Web of Science ®Google Scholar
• Jensen JC. Pharmacokinetics of Lamisil in humans. J Dermatol Treatment 1990;1(Suppl);15-18
   Google Scholar
• Back DJ, Tjia JF, Abel SM. Azoles, allylamines and drug metabolism. Br J Dermatology 1992;126(Suppl):14–18
   PubMed Web of Science ®Google Scholar
• Jensen P, Lehne G, Fauchald P, et al. Effect of oral terbinafine treatment on ciclosporin pharmacokinetics in organ transplant recipients with dermatophyte nail infection. Acta Derm Venereol 1996;76:280–1
   PubMed Web of Science ®Google Scholar
• Summerbell RC, Kane J, Krajden S. Onychomycosis, tinea pedis and tinea manuum caused by nondermatophytic filamentous fungi. Mycoses 1989;32:609–19.
   PubMed Web of Science ®Google Scholar
• English MP, Gibson MD. Studies in the epidemiology of tinea pedis. Br Med J 1959;15(5135):1442–6
   Google Scholar
• English MP, Wethered RR, Duncan EHL. Studies in the epidemiology of tinea pedis. VIII. Fungal infection in a long stay hospital. Br Med J 1967;3(558):136–139.
   Google Scholar
• Gentles JC, Holmes JG. Foot ringworm in coal-miners. Br J Industrial Med 1957;14:22–9
   PubMedGoogle Scholar
• Gentles JC, Evans EG. Foot infections in swimming baths. Br Med J 1973;3(5874):260–262.
   PubMedGoogle Scholar
• Howell SA, Clayton YM, Phan QG, et al. Tinea pedis: the relationship between symptoms, organisms and host characteristics. Microbiol Ecology Health Dis 1988;1:131–5
   Google Scholar
• Hay RJ, Clayton YM, de Silva N, et al. Tinea capitis in south-east London - a new pattern of infection with public health implications. Br J Dermatology 1996;135:955–8
   PubMed Web of Science ®Google Scholar
• Sharma V, Hall JC, Knapp JF, et al. Scalp colonisation by Trichophyton tonsurans in an urban pediatric clinic. Arch Dermatology 1988;124:1511–3
   PubMedGoogle Scholar
• Dupuy A. Risk factors for erysipelas of the leg (cellulitis): case control study. Br Med J 1999;318:1591–4
   PubMedGoogle Scholar
• Fuller LC, Child FC, Midgeley G, et al. Practical method for the diagnosis of scalp ringworm; validation of the toothbrush technique. J Europ Acad Derm Venereol 1997;9(Suppl):209
   Google Scholar
• Crawford F, Hart R, Bell-Syer F, et al. Topical treatment for fungal infections of the skin and nails of the foot (Cochrane Review). The Cochrane Library 2002: 4
   Google Scholar
• Berman B, Ellis C, Leyden J, et al. Efficacy of a 1-week, twice-daily regimen of terbinafine 1% cream in the treatment of interdigital tinea pedis. J Am Acad Dermatol 1992;26:956–60
   PubMed Web of Science ®Google Scholar
• Evans EGV, James IGV, Joshipura RC. Two week treatment of tinea pedis with terbinafine: a placebo controlled study. J Dermatological Treatment 1991;2:95–7
   Google Scholar
• Savin RC. Treatment of chronic tinea pedis (athletes foot type) with topical terbinafine. J Am Acad Dermatology 1990;23:786–9
   PubMedGoogle Scholar
• Savin RC, Atton AV, Bergstresser PR, et al. Efficacy of terbinafine 1% cream in the treatment of moccasin type tinea pedis: Results of placebo controlled multicentre trials. J Am Acad Dermatology 1994;30:663–7
   PubMedGoogle Scholar
• Smith EB, Noppakun N, Newton RC. A clinical trial of topical terbinafine (a new allylamine antifungal) in the treatment of tinea pedis. J Am Acad Dermatology 1990;23:790–4
   PubMedGoogle Scholar
• Ablon G, Rosen T, Spedale J. Comparative efficacy of naftifine, oxiconazole and terbinafine in short term treatment of tinea pedis. Int J Dermatology 1996;35:591–3
   PubMedGoogle Scholar
• Bergstresser PR, Elewski B, Hanifin J, et al. Topical terbinafine and clotrimazole in interdigital tinaea pedis: a multicentre comparison of cure and relapse rates with 1 and 4 week treatment regimens. J Am Acad Dermatology 1993;28:648–51
   PubMed Web of Science ®Google Scholar
• Evans EGV, Dodman B, Williamson DM, et al. Comparison of terbinafine and clotrimazole in treating tinea pedis. Br Med J 1993;307:645–7
   PubMedGoogle Scholar
• Sanchez-Carazo JL, Fuente C, Oliver V, et al. Estudio comparitivo de terbinafine vs. bifonazol crema al 1% en aplicacion unica diaria en tina pedis. Actas DermoSifiliograficas 1994;85:388–94
   Google Scholar
• Vermeer BJ, Staats CCG, Van Houweilingen JC. Terbinafine versus miconazol bij patienten met tinea pedis. Ned Tijdschr Geneeskd 1996;140:1605–8
   PubMedGoogle Scholar
• Korting HC, Tietz HJ, Braütigam M, et al. One week terbinafine 1% cream (Lamisil) once daily is effective in the treatment of interdigital tinea pedis: a vehicle controlled study. Med Mycology 2001;39:335–40
   PubMed Web of Science ®Google Scholar
• Patel A, Brookman D, Bullen MU, et al. Topical treatment of interdigital tinea pedis: terbinafine compared with clotrimazole. Aust J Dermatology 1999;40:197–200
   PubMedGoogle Scholar
• Leenutaphong V, Tangwiwat S, Muanprasat C, et al. Double-blind study of the efficacy of 1 week topical terbinafine cream compared to 4 weeks miconazole cream in patients with tinea pedis. J Med Assoc Thai 1999;82:1006–9
   PubMedGoogle Scholar
• Getting rid of athlete's foot. Drugs Ther Bulletin 2002;40:53–4
   Google Scholar
• Athlete's foot. Treatment Notes. Consumers association, 2002:23
   Google Scholar
• Villars V, Jones TC. Clinical efficacy and tolerability of terbinafine (Lamisil) - a new topical and systemic fungicidal drug for treatment of dermatomycosis. Clin Exp Dermatology 1989;14:124–7
   PubMed Web of Science ®Google Scholar
• Jones TC. Treatment of dermatomycosis with topically applied allylamines: naftifine and terbinafine. J Dermato-logical Treatment 1990;1(Suppl):29-32
   Google Scholar
• Kagawa S. Clinical efficacy of terbinafine in 629 Japanese patients with dermatomycosis. Clin Exp Dermatology 1989;14:114–5
   PubMed Web of Science ®Google Scholar
• Zaias N, Berman B, Cordero C, et al. Efficacy of a 1-week, once-daily regimen of terbinafine 1% cream in the treament of tinea cruris and tinea corporis. J Am Acad Dermatology 1993;29:646–8
   PubMedGoogle Scholar
• Budimulja U, Bramono K, Urip KS, et al. Once daily treatment with terbinafine 1% cream (Lamisil) for one week is effective in the treatment of tinea corporis and cruris. A placebo-controlled study. Mycoses 2001;44:300-6
   PubMedGoogle Scholar
• Evans EGV, Seaman RAJ, James IGV. Short-duration therapy with terbinafine 1% cream in dermatophyte skin infections. Br J Dermatology 1994;130:83–7
   PubMedGoogle Scholar
• Mieth H. In vitro and in vivo activities of terbinafine. In Rippon JW, Frontling RA, eds. Cutaneous Antifungal Agents in Clinical Dermatology. New York: Marcel Dekker, 1993:137–49
   Google Scholar
• Aste N, Pau M, Pinna AL, et al. Clinical efficacy and tolerability of terbinafine in patients with Pityriasis versicolor. Mycoses 1991;34:353–7
   PubMed Web of Science ®Google Scholar
• Faergemann J, Hersle K, Nordin P. Pityriasis versicolor: clinical experience with Lamisil cream and Lamisil Dermgel. Dermatology 1997;194(Suppl):19-21
   Google Scholar
• Faergemann J, Jones TC, Hettler O, et al. Pityrosporum ovale (Malassezia furfur) as the causative agent of seborrhoeic dermatitis: new treatment options. Br J Dermatology 1996;134(Suppl):12-15
   Google Scholar
• Bell-Syer SEM, Hart R, Crawford F, et al. Oral treatments for fungal infections of the skin of the foot (Cochrane Review). The Cochrane Library 2002;4
   Google Scholar
• Savin RC, Zaias N. Treatment of chronic moccasin-type tinea pedis with terbinafine: a double-blind placebo-controlled trial. J Am Acad Dermatology 1990;23:804–7
   PubMedGoogle Scholar
• Savin RC. Terbinafine (Lamisil) versus griseofulvin in moccasin-type tinea pedis. J Dermatol Treatment 1990;1(Suppl):43-6
   Google Scholar
• Widyanto, W Budimulja U, Kuswadji, et al. A randomized, double-blind comparative study of terbinafine versus griseofulvin in tinea pedis. In: Shuster S, Jafary MH, eds. Terbinafine in the Treatment of Superficial Fungal Infections. Asia-Pacific Symposium on Lamisil. London: Royal Society of Medicine Services, 1993: 21–4
   Google Scholar
• De Keyser P, De Backer M, Massart DL, et al. Two-week oral treatment for tinea pedis, comparing terbinafine (250 mg/day) with itraconazole (100 mg/day): a double-blind multicentre study. Br J Dermatology 1994;130(Suppl):22–5
   PubMed Web of Science ®Google Scholar
• Hay RJ, McGregor JM, White J, et al. A comparison of 2 weeks terbinafine 250mg/day with 4 weeks of itraconazole 100 mg/day in plantar-type tinea pedis. Br J Dermatology 1995;132:604–8
   PubMedGoogle Scholar
• Kim JH, Yoon KB. Single-blind randomized study of terbinafine versus itraconazole in tinea pedis (two weeks vs four weeks). In: Shuster S, Jafary MH, eds. Terbinafine in the Treatment of Superficial Fungal Infections. Asia-Pacific symposium on Lamisil. London: Royal Society of Medicine Services, 1993:17–20
   Google Scholar
• Voravutinon V. Double-blind comparative study of the efficacy and tolerability of terbinafine with itraconazole in patients with tinea pedis. In: Shuster S, Jafary MH, eds. Terbinafine in the Treatment of Superficial Fungal Infections. Asia-Pacific symposium on Lamisil. London: Royal Society of Medicine Services, 1993:11–16
   Google Scholar
• Hay RJ, Logan RA, Moore MK, et al. A comparative study of terbinafine versus griseofulvin in 'dry-type' dermatophyte infections. J Am Acad Dermatology 1991;24:243–6
   PubMedGoogle Scholar
• Tausch I, Decroix J, Gwiezdzinski Z, et al. Short-term itraconazole versus terbinafine in the treatment of tinea pedis or manus. Int J Dermatology 1998;37:128–44
   PubMedGoogle Scholar
• Barnetson RSC, Marley J, Bullen M, et al. Comparison of one week of oral terbinafine (250mg/day) with 4 weeks of treatment with clotrimazole 1% cream in interdigital tinea pedis. Br J Dermatology 1998;139:675–8
   PubMed Web of Science ®Google Scholar
• Frieden IJ, Howard R. Tinea capitis: Epidemiology, diagnosis, treatment and control. J Am Acad Dermatology 1994;31:542–6
   Google Scholar
• Babel DE, Baughman A. Evaluation of the adult carrier state in juvenile tinea capitis caused by Trichophyton tonsurans. J Am Acad Dermatology 1989;21:1209–12
   PubMed Web of Science ®Google Scholar
• Haroon TS, Hussain I, Mahmood I, et al. An open clinical pilot study of the efficacy and safety of oral terbinafine in dry non-inflammatory tinea capitis. Br J Dermatology 1992;126(Suppl):47-50
   Google Scholar
• Haroon TS, Hussain T, Aman S, et al. A randomized double-blind comparitive study of terbinafine and griseofulvin in tinea capitis. J Dermatol Treatment 1995;6;167-9
   Google Scholar
• Fuller LC, Smith CH, Cerio R, et al. A randomized comparison of 4 weeks of terbinafine vs 8 weeks of griseofulvin for the treatment of tinea capitis. Br J Dermatol 2001;144:321–7
   PubMed Web of Science ®Google Scholar
• Jahangir M, Hussain I, Hasan M, et al. A double-blind randomized, comparative trial of itraconazole versus terbinafine for 2 weeks in tinea capitis. Br J Dermatology 1998;139:672–4
   PubMedGoogle Scholar
• Hamm H, Schwinn A, Braütigam M, et al. Short duration treatment with terbinafine for tinea capitis caused by Trichophyton or Microsporum species. Br J Dermatology 1999;140:480–2
   PubMedGoogle Scholar
• Fuller LC, Child FJ, Midgeley G, et al. Diagnosis and management of scalp ringworm. Br Med J 2003;326:539–41
   Google Scholar
• Jones TC. Overview of the use of terbinafine (Lamisil) in children. Br J Dermatology 1995;132:683–9
   PubMed Web of Science ®Google Scholar
• Baudraz-Rosselet F, Monod M, Jaccoud S, et al. Efficacy of terbinafine treatment of tinea capitis varies according to the dermatophyte species. Br J Dermatology 1996;135:1011
   Google Scholar
• Villars V, Jones TC. Present status of the efficacy and tolerability of terbinafine (Lamisil) used systemically in the treatment of dermatomycosis of skin and nails. J Dermatological Treatment 1990;1(Suppl):33-8
   Google Scholar
• Voravutinon V. Oral treatment of tinea corporis and cruris with terbinafine and griseofulvin: a randomized double blind comparitive study. J Med Assoc Thai 1993;76:388–93
   PubMedGoogle Scholar
• Farag A, Taha M, Halim S. One week therapy with oral terbinafine in cases of tinea cruris/corporis. Br J Dermatology 1994;131:684–6
   PubMed Web of Science ®Google Scholar
• Harris J. Do crinkly toenails really matter? Br Med J 1999;319:1197
   Google Scholar
• Stone N, Dawber R. Toenail onychomycosis can cause serious problems. Br Med J 2000;320:448
   Google Scholar
• Crawford F, Young P, Godfrey C, et al. Oral treatments for fungal infections of the toenails. Protocol for a Cochrane Review. The Cochrane Library 2002;4
   Google Scholar
• Goodfield MJD. Short-duration therapy with terbinafine for dermatophyte onychomycosis: a multicentre trial. Br J Dermatology 1992;126(Suppl):33-5
   Google Scholar
• Drake LA, Shere NH, Arlette JP, et al. Oral terbinafine in the treatment of toenail onychomycosis. J Am Acad Dermatology 1997;37:740–5
   PubMed Web of Science ®Google Scholar
• Svejfaard EL, Brandrup F, Kragballe K, et al. Oral terbinafine in toenail dermatophytosis. Acta Derm Venereol 1997;77:66–9
   PubMedGoogle Scholar
• Hofmann H, Brautigam M, Weidinger G, et al. Treatment of toenail onychomycosis. Arch Dermatol 1995;131:919–22
   Google Scholar
• De Backer M, De Keyser P, De Vroey C, et al. A 12 week treatment for dermatophyte toe onychomycosis: terbinafine 250 mg/day versus itraconazole 200 mg/day - a double-blind comparitive trial. Br J Dermatology 1996;134(Suppl):16–17
   PubMed Web of Science ®Google Scholar
• Brautigam M, Nolting S, Schopf RE, et al. Randomized double-blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. Br Med J 1995;311:919–22
   PubMed Web of Science ®Google Scholar
• Evans EGV, Sigurgeirsson B. Double-blind, randomized study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. Br Med J 1999;318:1031–5
   PubMed Web of Science ®Google Scholar
• Sigurgeirsson B, Olafsson JH, Steinsson JP, et al. Long-term effectiveness of treatment with terbinafine versus itraconazole in onychomycosis. Arch Dermatol 2002;138:353–7
   PubMed Web of Science ®Google Scholar
• Roberts DT. Oral therapeutic agents in fungal nail disease. J Am Acad Dermatology 1994;31:578–81
   Google Scholar
• Denning DW, Evans EGV, Kibbler CC, et al. Fungal nail disease: a guide to good practice (report of a Working Group of the British Society for Medical Mycology). Br Med J 1995;311:1277–81
   PubMed Web of Science ®Google Scholar
• Crawford F, Young P, Godfrey C, et al. Oral treatments for toenail onychomycosis. Arch Dermatology 2002;138:811–6
   PubMed Web of Science ®Google Scholar
• Haugh M, Helon S, Boissel JP, et al. Terbinafine in fungal infections of the nails: a meta-analysis of randomized clinical trials. Br J Dermatology 2002;147:118–21
   PubMed Web of Science ®Google Scholar
• Roberts DT, Talyor WD, Boyle J. Guidelines for treatment of onychomycosis. Br J Dermatology 2003;148:402–10
   PubMed Web of Science ®Google Scholar
• Alpsoy E, Yilmaz E, Basaran E. Intermittent therapy with terbinafine for dermatophyte toe onychomycosis: A new approach. J Dermatology 1996;23:259–62
   PubMedGoogle Scholar
• Tosti A, Piraccini BM, Stinchi C, et al. Treatment of dermatophyte nail infections: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy. J Am Acad Dermatology 1996;34:595–600
   PubMed Web of Science ®Google Scholar
• Van der Schroeff JG, Cirkel PKS, Crijins MB, et al. A randomized treatment duration-finding study of terbinafine in onychomycosis. Br J Dermatology 1992; 126(Suppl):36–9
   PubMed Web of Science ®Google Scholar
• Olafsson JH, Sigurgeirsson B, Baran R. Combination therapy for onychomycosis. Br J Dermatology 2003; 149(Suppl):15-18
   Google Scholar
• Gianni C, Cerri A, Crosti C. Unusual clinical features of fingernail infection by Fusarium oxysporum. Mycoses 1997;40:455–9
   PubMedGoogle Scholar
• Budimulja U, Kuswadji K, Bramano S, et al. A double-blind, randomized, stratified controlled study of the treatment of tinea imbricata with oral terbinafine or itraconazole. Br J Dermatology 1994;130(Suppl):29-31
   Google Scholar
• Wingfield AB, Fernandez-Obregon AC, Wignall FS, et al. Treatment of tinea imbricata: a randomized clinical trial using griseofulvin, terbinafine, itraconazole and fluconazole. Br J Dermatology 2004;150:119–126
   PubMedGoogle Scholar
• Gip L. Black piedra: the first case treated with terbinafine (Lamisil). Br J Dermatology 1994;130(Suppl):26-8
   Google Scholar
• Hull PR, Vismet HF. Treatment of cutaneous sporotrichosis with terbinafine. Br J Dermatology 1992; 126(Suppl):51-5
   Google Scholar
• Schiraldi GF, Lo Cicero S, Colombo MD, et al. Refractory pulmonary aspergillosis: compassionate trial with terbinafine. Br J Dermatology 1996;134(Suppl): 25–9
   PubMed Web of Science ®Google Scholar
• Esterre P, Inzan Ck, Ramarcel ER, et al. Treatment of chromomycosis with terbinafine: preliminary results of an open pilot study. Br J Dermatology 1996;134(Suppl): 33–6
   PubMed Web of Science ®Google Scholar
• Villars VV, Jones TC. Special features of the clinical use of oral terbinafine in the treatment of fungal diseases. Br J Dermatology 1996;126(Suppl):61–9
   Google Scholar
• Nandwani R, Parnell A, Youle M, et al. Use of terbinafine in HIV-positive subjects: pilot studies in onychomycosis and oral candidiasis. Br J Dermatology 1996; 134(Suppl):22–4
   PubMedGoogle Scholar
• Herranz P, Garcaia J, De Lucas R, et al. Toenail onychomycosis in patints with acquired immune deficiency syndrome; treatment with terbinafine. Br J Dermatology 2004;150;414–20
   PubMedGoogle Scholar
• Smith S, Houpt K, Rich P, et al. Short duration oral terbinafine for the treatment of tinea pedis in HIV-positive patients. Cutis 2001;68(Suppl):30–9
   PubMedGoogle Scholar
• Rich P, Houpt K, LaMarca A, et al. Safety and efficacy of short duration oral terbinafine for the treatment of tinea corporis or tinea cruris in subjects with HIV infection or diabetes. Cutis 2001;68(Suppl):15–22
   PubMedGoogle Scholar
• Cribier BJ, Bakshi R. Terbinafine in the treatment of onychomycosis: a review of its efficacy in high-risk populations and in patients with nondermatophyte infections. Br J Dermatology 2004;150:414–20
   PubMed Web of Science ®Google Scholar
• Committee on Safety of Medicines. Personal communication, 2004
   Google Scholar
• Hall M, Monka C, Krupp P, O'Sullivan D. Safety of oral terbinafine. Arch Dermatol 1997;133:1213–9
   PubMed Web of Science ®Google Scholar
• O'Sullivan DP, Needham CA, Bangs A, et al. Post marketing surveillance of oral terbinafine in the UK: report of a large cohort study Br J Clin Pharmacol 1996;42:559–65
   Google Scholar
• Roberts DT. Systemic antifungals as a cause of liver damage. Prescribers J 1998;38:190–4
   Google Scholar
• Lovell MO, Speeg KV, Havranek RD. Histological changes resembling acute rejection in a liver transplant recipient treated with terbinafine. Human Pathology 2003;34:187–9
   PubMed Web of Science ®Google Scholar
• Humphrey KM, Court MJ, Haycocks A. A retrospective cost effectiveness analysis of the treatment of onychomycosis in general practice. Br J Dermatology 1998; 139:660–4
   PubMed Web of Science ®Google Scholar
• Jensen R, Redekop WK, Rutten FH. Cost effectiveness of continuous terbinafine compared with intermittent itraconazole in the treatment of dermatophyte toenail onychomycosis. Pharmacoeconomics 2001;19:401–10
   PubMedGoogle Scholar
• Marchetti A, Piech KT, McGhan WF, et al. Pharmacoeconomic analysis of oral therapies for onychomycosis: a US model. Clin Ther 1996;18:757–7
   PubMedGoogle Scholar
• Bootman JL. Cost-effectiveness of two new treatments for onychomycosis; an analysis of two comparative clinical trials. J Am Acad Dermatology 1998;38:569–72
   PubMedGoogle Scholar
• Van Doorslar EKA, Tormans G, Gupta AK, et al. Economic evaluation of antifungal agents in the treatment of toenail onychomycosis in Germany. Pharmacology Treatment 1996;193:239–44
   Google Scholar
• Gupta AK. Pharmacoeconomic analysis of oral antifungal therapies used to treat dermatophyte oychomycosis of the toenails Pharmacoeconomics 1998;13:243–56
   Google Scholar